Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CET

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01/17 SANOFI : SuliquaTM Approved in the European Union for the Treatment of Adults wi..
01/17 SANOFI : SuliquaTM Approved in the European Union for the Treatment of Adults wi..
01/17 SANOFI : Human Rights Day at Sanofi
01/16 SANOFI : Disclosure of trading in own shares
01/16 SANOFI : Disclosure of trading in own shares
01/13 SANOFI : MILITARY $3.2 Million Federal Contract Awarded to Sanofi Pasteur
01/13 SANOFI : MILITARY $526,056 Federal Contract Awarded to Sanofi Pasteur
01/13 SANOFI : MILITARY $192,418 Federal Contract Awarded to Sanofi Pasteur
01/13 SANOFI : MILITARY $1.85 Million Federal Contract Awarded to Sanofi Pasteur
01/12 SANOFI : and Boehringer Ingelheim Confirm Closing of Business Swap on January 1s..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJBayer Joins Jobs Parade -- WSJ
01:56aDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
12:05aDJAllergan Admits to Disclosure Violations During Valeant Bid
01/17 Allergan to pay $15 million over failing to disclose merger talks
01/17DJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:21a Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
01/17 MANNKIND : Afrezza Sales Start Off 2017 Modestly. Will A Bigger Sales Force Make..
01/16 PFIZER : 2 Risks Every Shareholder Should Be Aware Of
01/13 SANOFI : Key Threats In 2017 And Beyond
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
Advertisement
Financials (€)
Sales 2016 36 734 M
EBIT 2016 9 202 M
Net income 2016 5 242 M
Debt 2016 6 114 M
Yield 2016 3,85%
P/E ratio 2016 16,74
P/E ratio 2017 14,98
EV / Sales 2016 2,84x
EV / Sales 2017 2,84x
Capitalization 98 349 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 81,0 €
Spread / Average Target 6,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.01%105 039
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results